Navigation Links
Gevo Doesn't Infringe Butamax's '017 Patent; Gevo was First to Invent Enzyme in '017 Patent; Gevo has Advanced Beyond That and Now Uses Different Enzymes
Date:8/8/2012

ENGLEWOOD, Colo., Aug. 8, 2012 /PRNewswire/ -- Gevo, Inc. (NASDAQ: GEVO), a leading renewable chemicals and next-generation biofuels company, said today that the latest lawsuit filed by Butamax™ Advanced Biofuels LLC (Butamax) alleging infringement by Gevo of Butamax's U.S. Patent No. 8,222,017 ('017 Patent), like the last one filed by Butamax against Gevo, will be shown to have no merit.  Gevo said it is also challenging the validity of Butamax's '017 Patent.

"We don't infringe the enzyme claimed in Butamax's patent," said Brett Lund, Executive Vice President and General Counsel of Gevo. "Gevo previously developed and patented a modified E. coli KARI enzyme, and since then, our technology has advanced well beyond this. Our industry-leading process now utilizes an enzyme that is not derived from, or in any way related, to the E. coli KARI enzyme described in the newly issued patent. We provided proof of our non-infringement to Butamax and they still sued us." 

"We also challenge the validity of the just-issued Butamax patent. We strongly believe that Gevo was the first to invent the claimed subject matter," Lund said. "Therefore, we have filed a 'Request for Interference' (Serial No. 13/271,084) with the U.S. Patent and Trademark Office to demonstrate that the technology is, in fact, a Gevo invention. Gevo's technology represents the industry standard for the optimization of the native yeast isobutanol pathway. Our commitment to innovation is what sustains this leadership position. We see this unfounded lawsuit as another attempt by Butamax to stall our significant advances in the commercialization of renewable isobutanol."

"This lawsuit is part and parcel of an ongoing effort by Butamax and its corporate parents, DuPont and British Petroleum, to divert attention from the well-established fact that much of Butamax's technology is based on invalid patents and that Gevo is the real innovator in this field," he said.

"The timing of Butamax's new litigation is curious, to say the least, coming the day before our quarterly earnings call," Lund said. "It also appears retaliatory, coming late on the same day we announced we were filing a motion for a preliminary injunction to halt their ongoing infringement of a Gevo patent."

"In April, the highly respected Biofuels Digest wrote, 'you be the judge on the merits of the timing, right in the middle of Gevo's IPO road show, Butamax sued Gevo over infringement of the patents.' Butamax also has initiated litigation timed to coincide with Gevo's secondary offering, and filed reexamination requests at the USPTO timed to coincide with the announcement of the startup of Gevo's commercial-scale production facility in Minnesota.  Many other such juxtapositions have occurred. We don't think it's coincidental. We believe this latest litigation, like all prior Butamax lawsuits, is without merit."

About Gevo

Gevo is converting existing ethanol plants into biorefineries to make renewable building block products for the chemical and fuel industries. The Company plans to convert renewable raw materials into isobutanol and renewable hydrocarbons that can be directly integrated on a "drop-in" basis into existing chemical and fuel products to deliver environmental and economic benefits. Gevo is committed to a sustainable biobased economy that meets society's needs for plentiful food and clean air and water. For more information, visit www.gevo.com 

Forward-Looking Statements

Certain statements in this press release may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements that are not purely statements of historical fact, and can sometimes be identified by our use of terms such as "intend," "expect," "plan," "estimate," "future," "strive" and similar words. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Gevo and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and the company undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although the company believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Gevo in general, see the risk disclosures in the Annual Report on Form 10-K of Gevo for the year ended December 31, 2011, as amended, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the SEC by Gevo.


'/>"/>
SOURCE Gevo, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Butamax™ Responds to Gevo Patent Infringement Lawsuit
2. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
3. Avaxia Biologics, Inc. Raises $2.2 Million in First Closing of Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease
4. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
5. Fitzsimons Redevelopment Authority Rolls Out First Phase of Strategic Refocus With Appointment of Four Key Leaders in The Bioscience Industry to Its Board of Directors
6. Webcor Builders Selected as the General Contractor for First Phase of LA BioMeds New Campus Master Plan
7. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2012 Financial Results
8. Tiger Woods Gives Exclusive First Interview Since POWERED by FUSE Announcement!
9. The Pharmabiotic Research Institute (PRI) is Preparing to Publish its First Works on the Therapeutic and Medicinal Potential of Probiotics
10. Eye Surgery Center of Michigan First in Southeast Michigan to Perform Bladeless Cataract Surgery Using New LenSx® Laser Technology
11. Amgen Announces 2012 First Quarter Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016  The Prostate Cancer Foundation (PCF) is pleased ... and faster cures for prostate cancer. Members of the Class of 2016 were ... Read More About the Class of 2016 PCF Young ... ... ...
(Date:6/23/2016)... NC (PRWEB) , ... June 23, 2016 , ... In ... University Hospital in Denmark detail how a patient who developed lymphedema after being treated ... tissue. The results could change the paradigm for dealing with this debilitating, frequent side ...
(Date:6/23/2016)... Francisco, CA (PRWEB) , ... June 23, 2016 ... ... (EDC) software, is exhibiting at the Pennsylvania Convention Center and will showcase its ... Annual conference. ClinCapture will also be presenting a scientific poster on Disrupting Clinical ...
(Date:6/22/2016)... June 22, 2016 Cell Applications, Inc. ... them to produce up to one billion human ... within one week. These high-quality, consistent stem cells ... cells and spend more time doing meaningful, relevant ... proprietary, high-volume manufacturing process that produces affordable, reliable ...
Breaking Biology Technology:
(Date:5/9/2016)... Elevay is currently known as ... for high net worth professionals seeking travel for work ... world, there is still no substitute for a face-to-face ... your deal with a firm handshake. This is why ... of citizenship via investment programs like those offered by ...
(Date:4/26/2016)... , April 27, 2016 ... the  "Global Multi-modal Biometrics Market 2016-2020"  report to ... ) , The analysts forecast the ... CAGR of 15.49% during the period 2016-2020.  ... number of sectors such as the healthcare, BFSI, ...
(Date:4/13/2016)... CHICAGO , April 13, 2016  IMPOWER physicians ... are setting a new clinical standard in telehealth ... By leveraging the higi platform, IMPOWER patients can ... weight, pulse and body mass index, and, when they ... quick and convenient visit to a local retail location ...
Breaking Biology News(10 mins):